Evidence map›Paper›PMID 25534732›Full record

ArticleAntimicrobial agents and chemotherapy2015

The MSPDBL2 codon 591 polymorphism is associated with lumefantrine in vitro drug responses in Plasmodium falciparum isolates from Kilifi, Kenya.

Lynette Isabella Ochola-Oyier, John Okombo, Leah Mwai, Steven M Kiara, Lewa Pole, Kevin K A Tetteh, Alexis Nzila, Kevin Marsh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lynette Isabella Ochola-OyierKenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Kilifi, Kenya liochola@kemri-wellcome.org.
John OkomboKenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Kilifi, Kenya.
Leah MwaiKenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Kilifi, Kenya.
Steven M KiaraKenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Kilifi, Kenya.
Lewa PoleKenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Kilifi, Kenya.
Kevin K A TettehDepartment of Immunology & Infection, Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Alexis NzilaKing Fahd University of Petroleum and Minerals, Department of Biology, Dhahran, Saudi Arabia.
Kevin MarshKenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Kilifi, Kenya.

Funding

Wellcome Trust 092654
6 · The paper itself

Abstract

The mechanisms of drug resistance development in the Plasmodium falciparum parasite to lumefantrine (LUM), commonly used in combination with artemisinin, are still unclear. We assessed the polymorphisms of Pfmspdbl2 for associations with LUM activity in a Kenyan population. MSPDBL2 codon 591S was associated with reduced susceptibility to LUM (P = 0.04). The high frequency of Pfmspdbl2 codon 591S in Kenya may be driven by the widespread use of lumefantrine in artemisinin combination therapy (Coartem).

Indexed as

AntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsCodonDrug CombinationsDrug ResistanceEthanolaminesFluorenesHumansKenyaLumefantrineMalaria, FalciparumPlasmodium falciparumPolymorphism, GeneticProtozoan ProteinsAntimalarialsArtemether, Lumefantrine Drug CombinationartemisininArtemisininsCodonDrug CombinationsEthanolaminesFluorenesLumefantrineProtozoan Proteins

Identifiers

PMID25534732
PMCPMC4325780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.